Aatiqah Aziz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Aatiqah Aziz has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Mayur Virarkar
Department of Radiology, University of Florida, Jacksonville, FL, USA
4 shared publications - Priya Bhosale
The University of Texas MD Anderson Cancer Center, Houston, USA
4 shared publications - Jia Sun
The University of Texas MD Anderson Cancer Center, Houston, USA
3 shared publications - Michael Frumovitz
Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
2 shared publications - Revathy B. Iyer
The University of Texas MD Anderson Cancer Center, Houston, USA
2 shared publications - Sanaz Javadi
The University of Texas MD Anderson Cancer Center, Houston, USA
2 shared publications
Latest Publications
- 18 November 2025
- Published by Springer Nature in Abdominal Radiology
- Vol. 51 (6) , 3102-3114
Comparative efficacy and workflow efficiency of integrated PET/MRI versus sequential PET/CT and MRI in gynecologic cancer staging: a prospective single-center study
Aim To compare the diagnostic performance of PET/MRI versus PET/CT for lymph node and metastatic disease detection in patients with gynecologic cancers, and to assess whether PET/MRI offers improved staging accuracy and operational efficiency. Materials 49 patients with known gynecologic malignancies underwent both PET/CT and PET/MRI as part of a prospective study. Imaging protocols followed standard guidelines for each modality, with PET/CT and PET/MRI performed consecutively. Images were independently evaluated by experienced radiologists who assessed primary tumor, nodal, and metastatic disease. Subgroup analysis was performed for cervical cancer patients. Each patient’s time in the imaging department for each scan was recorded, and statistical analysis included calculation of sensitivity, specificity, McNemar testing, and Cohen’s Kappa for inter-rater agreement. Results This study prospectively confirms prior findings of PET/MRI’s superior nodal detection in gynecologic cancers while providing novel evidence regarding operational efficiency and workflow optimization. PET/MRI demonstrated superior detection of nodal metastases compared to PET/CT, identifying additional adenopathy in 5 patients (p = 0.031) and leading to staging changes in 18 patients within the cohort. In the cervical cancer subset, PET/MRI resulted in more upstaging and downstaging events, though subgroup statistical significance was not reached. PET/MRI also identified more primary tumors missed by PET/CT. The average total imaging time was significantly reduced with PET/MRI (180.3 min) compared to the combined PET/CT and MRI workflow (291.2 min), reflecting a 38.1% reduction in time burden. Qualitative assessment rated PET/MRI superior to PET/CT in 67.3% of cases. Conclusion While diagnostic superiority confirms current literature, this study provides the first prospective quantitative assessment of workflow efficiency in gynecologic oncology imaging. PET/MRI outperforms PET/CT in the detection of nodal disease and in overall diagnostic evaluation for patients with gynecologic cancers. In addition to superior staging accuracy, PET/MRI reduces patient time burden, supporting its use as a preferred, patient-centric imaging modality. Wider clinical adoption and further research are warranted to validate these findings in larger, multi-institutional cohorts.
- 18 November 2025
- Published by Springer Nature in Abdominal Radiology
- Vol. 51 (6) , 3102-3114
Comparative efficacy and workflow efficiency of integrated PET/MRI versus sequential PET/CT and MRI in gynecologic cancer staging: a prospective single-center study
Aim To compare the diagnostic performance of PET/MRI versus PET/CT for lymph node and metastatic disease detection in patients with gynecologic cancers, and to assess whether PET/MRI offers improved staging accuracy and operational efficiency. Materials 49 patients with known gynecologic malignancies underwent both PET/CT and PET/MRI as part of a prospective study. Imaging protocols followed standard guidelines for each modality, with PET/CT and PET/MRI performed consecutively. Images were independently evaluated by experienced radiologists who assessed primary tumor, nodal, and metastatic disease. Subgroup analysis was performed for cervical cancer patients. Each patient’s time in the imaging department for each scan was recorded, and statistical analysis included calculation of sensitivity, specificity, McNemar testing, and Cohen’s Kappa for inter-rater agreement. Results This study prospectively confirms prior findings of PET/MRI’s superior nodal detection in gynecologic cancers while providing novel evidence regarding operational efficiency and workflow optimization. PET/MRI demonstrated superior detection of nodal metastases compared to PET/CT, identifying additional adenopathy in 5 patients (p = 0.031) and leading to staging changes in 18 patients within the cohort. In the cervical cancer subset, PET/MRI resulted in more upstaging and downstaging events, though subgroup statistical significance was not reached. PET/MRI also identified more primary tumors missed by PET/CT. The average total imaging time was significantly reduced with PET/MRI (180.3 min) compared to the combined PET/CT and MRI workflow (291.2 min), reflecting a 38.1% reduction in time burden. Qualitative assessment rated PET/MRI superior to PET/CT in 67.3% of cases. Conclusion While diagnostic superiority confirms current literature, this study provides the first prospective quantitative assessment of workflow efficiency in gynecologic oncology imaging. PET/MRI outperforms PET/CT in the detection of nodal disease and in overall diagnostic evaluation for patients with gynecologic cancers. In addition to superior staging accuracy, PET/MRI reduces patient time burden, supporting its use as a preferred, patient-centric imaging modality. Wider clinical adoption and further research are warranted to validate these findings in larger, multi-institutional cohorts.
- 29 October 2025
- Published by Springer Nature in Abdominal Radiology
- Vol. 51 (5) , 2615-2630
Insights into endometrial cancer management: a comprehensive guide through multimodality imaging
Endometrial cancer is the most common gynecologic malignancy in developed countries, exhibiting significant heterogeneity in prognosis and management. This review highlights the critical role of multimodality imaging—including ultrasound, MRI, CT, and PET/CT—at every stage of care, from initial diagnosis and risk stratification to surgical planning, treatment selection, and surveillance. Imaging enables accurate tumor characterization, local and distant staging, and detection of nodal and peritoneal disease, but also significantly influences the choice between conservative and radical surgery, sentinel lymph node mapping, and individualized adjuvant therapies. Advances in functional and quantitative imaging, such as DWI, have improved precision in disease grading and treatment tailoring. Core learning points include the necessity of standardized management algorithms, the importance of multiparametric assessments for optimal risk stratification, and the evolving potential of imaging biomarkers to personalize endometrial cancer management and improve patient outcomes.
- 29 October 2025
- Published by Springer Nature in Abdominal Radiology
- Vol. 51 (5) , 2615-2630
Insights into endometrial cancer management: a comprehensive guide through multimodality imaging
Endometrial cancer is the most common gynecologic malignancy in developed countries, exhibiting significant heterogeneity in prognosis and management. This review highlights the critical role of multimodality imaging—including ultrasound, MRI, CT, and PET/CT—at every stage of care, from initial diagnosis and risk stratification to surgical planning, treatment selection, and surveillance. Imaging enables accurate tumor characterization, local and distant staging, and detection of nodal and peritoneal disease, but also significantly influences the choice between conservative and radical surgery, sentinel lymph node mapping, and individualized adjuvant therapies. Advances in functional and quantitative imaging, such as DWI, have improved precision in disease grading and treatment tailoring. Core learning points include the necessity of standardized management algorithms, the importance of multiparametric assessments for optimal risk stratification, and the evolving potential of imaging biomarkers to personalize endometrial cancer management and improve patient outcomes.
- Open Access
Evaluating the Diagnostic Performance of PET/MR Versus CECT in Determining Resectability in Ovarian Cancer
Objective: This study aimed to compare the diagnostic accuracy of whole-body PET/MR imaging and contrast-enhanced CT for detecting metastatic disease in patients undergoing surgical resection, using pathology as the reference standard. Materials and Methods: Nineteen patients with suspected metastatic involvement (including four who received neoadjuvant therapy before surgery) underwent both FDG PET/MR and contrast-enhanced CT scans. Imaging was reviewed for metastases at defined sites (e.g., perihepatic region, hepatic parenchyma, mesentery, bowel serosa, colon surface, and nodal basins). Findings on each modality were compared to surgical pathology results per site. Sensitivity, specificity, accuracy, positive predictive value (PPV), and negative predictive value (NPV) were calculated for PET/MR and CT, with pathology as the reference standard. Results: Overall, PET/MR achieved approximately 55.5% sensitivity, 89.5% specificity, 82.5% accuracy, 57.6% positive predictive value (PPV), and 88.6% negative predictive value (NPV). In contrast, CT demonstrated 75.0% sensitivity, 72.3% specificity, 72.9% accuracy, 42% PPV, and 91.5% NPV. No significant correlations were observed between semi-quantitative PET/MR measures, such as SUV or MR ADC values, and patient survival outcomes; therefore, these metrics were excluded from further analysis. Notably, PET/MR imaging findings changed clinical management in 3/6 chemotherapy patients. PET/MR demonstrated greater sensitivity in detecting nodal metastases, 75% compared to CT (25%), and identified small bowel serosal lesions in 1 of 1 case (100% sensitivity) versus none with CT. CT showed slightly higher specificity (81%) for colon serosal involvement than PET/MR (75%). Conclusions: CT demonstrates higher sensitivity, whereas PET/MR offers greater specificity and negative predictive value. When used together, the two modalities may provide a more reliable and comprehensive assessment of metastatic disease.
Open AccessEvaluating the Diagnostic Performance of PET/MR Versus CECT in Determining Resectability in Ovarian Cancer
Objective: This study aimed to compare the diagnostic accuracy of whole-body PET/MR imaging and contrast-enhanced CT for detecting metastatic disease in patients undergoing surgical resection, using pathology as the reference standard. Materials and Methods: Nineteen patients with suspected metastatic involvement (including four who received neoadjuvant therapy before surgery) underwent both FDG PET/MR and contrast-enhanced CT scans. Imaging was reviewed for metastases at defined sites (e.g., perihepatic region, hepatic parenchyma, mesentery, bowel serosa, colon surface, and nodal basins). Findings on each modality were compared to surgical pathology results per site. Sensitivity, specificity, accuracy, positive predictive value (PPV), and negative predictive value (NPV) were calculated for PET/MR and CT, with pathology as the reference standard. Results: Overall, PET/MR achieved approximately 55.5% sensitivity, 89.5% specificity, 82.5% accuracy, 57.6% positive predictive value (PPV), and 88.6% negative predictive value (NPV). In contrast, CT demonstrated 75.0% sensitivity, 72.3% specificity, 72.9% accuracy, 42% PPV, and 91.5% NPV. No significant correlations were observed between semi-quantitative PET/MR measures, such as SUV or MR ADC values, and patient survival outcomes; therefore, these metrics were excluded from further analysis. Notably, PET/MR imaging findings changed clinical management in 3/6 chemotherapy patients. PET/MR demonstrated greater sensitivity in detecting nodal metastases, 75% compared to CT (25%), and identified small bowel serosal lesions in 1 of 1 case (100% sensitivity) versus none with CT. CT showed slightly higher specificity (81%) for colon serosal involvement than PET/MR (75%). Conclusions: CT demonstrates higher sensitivity, whereas PET/MR offers greater specificity and negative predictive value. When used together, the two modalities may provide a more reliable and comprehensive assessment of metastatic disease.
- 21 July 2025
- Published by Elsevier in Journal of the American College of Radiology
- Vol. 22 (11) , 1443
Patient-Friendly Summary of the ACR Appropriateness Criteria®: Acute Spinal Trauma: 2025 Update
- 21 July 2025
- Published by Elsevier in Journal of the American College of Radiology
- Vol. 22 (11) , 1443
Patient-Friendly Summary of the ACR Appropriateness Criteria®: Acute Spinal Trauma: 2025 Update
- 19 June 2025
- Published by Elsevier in Journal of the American College of Radiology
- Vol. 22 (10) , 1255
Patient-Friendly Summary of the ACR Appropriateness Criteria®: Female Breast Cancer Screening: 2025 Update
- 19 June 2025
- Published by Elsevier in Journal of the American College of Radiology
- Vol. 22 (10) , 1255
Patient-Friendly Summary of the ACR Appropriateness Criteria®: Female Breast Cancer Screening: 2025 Update
- 27 November 2024
- Published by Springer Nature in Abdominal Radiology
- Vol. 50 (6) , 2703-2709
Impact of metastasis site on overall survival in neuroendocrine cervical carcinoma
- 27 November 2024
- Published by Springer Nature in Abdominal Radiology
- Vol. 50 (6) , 2703-2709
Impact of metastasis site on overall survival in neuroendocrine cervical carcinoma
- 13 November 2024
- Published by Elsevier in Journal of the American College of Radiology
- Vol. 22 (5) , 615
Patient-Friendly Summary of the ACR Appropriateness Criteria®: Female Breast Cancer Screening: 2024 Update
- 13 November 2024
- Published by Elsevier in Journal of the American College of Radiology
- Vol. 22 (5) , 615
Patient-Friendly Summary of the ACR Appropriateness Criteria®: Female Breast Cancer Screening: 2024 Update
- 18 October 2024
- Published by Elsevier in Journal of the American College of Radiology
- Vol. 22 (2) , 246
Patient-Friendly Summary of the ACR Appropriateness Criteria®: Pretreatment Staging of Urothelial Cancer: 2024 Update
- 18 October 2024
- Published by Elsevier in Journal of the American College of Radiology
- Vol. 22 (2) , 246
Patient-Friendly Summary of the ACR Appropriateness Criteria®: Pretreatment Staging of Urothelial Cancer: 2024 Update
- Open Access
- 24 October 2023
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 33 (11) , 1690-1694
PET/CT scan improves detection of metastatic disease compared with CT scan alone in women with high-grade neuroendocrine cervical cancer: a NeCTuR study
Objective To determine the optimal imaging modality for women with high-grade neuroendocrine carcinoma of the cervix. Methods Women with high-grade neuroendocrine carcinoma of the cervix who had undergone a computed tomography (CT) scan and combined positron emission tomography with computed tomography (PET/CT) scan within 4 weeks of each other were identified from the NeCTuR Cervical Tumor Registry. One radiologist reviewed all CT scans, and another radiologist reviewed all PET/CT scans. The radiologists denoted the presence or absence of disease at multiple sites. Each radiologist was blinded to prior reports, patient outcomes, and the readings of the other radiologist. With findings on PET/CT used as the gold standard, sensitivity, specificity, and accuracy were calculated for CT scans. Results Fifty matched CT and PET/CT scans were performed in 41 patients. For detecting primary disease in the cervix, CT scan had a sensitivity of 85%, a specificity of 46%, and an accuracy of 74%. For detecting disease spread to the liver, CT scan had a sensitivity of 80%, a specificity of 89%, and an accuracy of 86%. For detecting disease spread to the lung, CT had a sensitivity of 89%, a specificity of 68%, and an accuracy of 77%. Of the 14 patients who had scans for primary disease work-up, 4 (29%) had a change in their treatment plan due to the PET/CT scan. Had treatment been prescribed on the basis of the CT scan alone, 2 patients would have been undertreated, and 2 would have been overtreated. Conclusion A CT scan is inferior to a PET/CT scan in assessment of metastatic disease in women with high-grade neuroendocrine carcinoma of the cervix. Almost one-third of patients with newly diagnosed high-grade neuroendocrine cervical cancer would have received incorrect therapy had treatment planning been based solely on a CT scan. We recommend a PET/CT scan for both initial work-up and surveillance in women with high-grade neuroendocrine carcinoma of the cervix.
- 24 October 2023
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 33 (11) , 1690-1694
Open AccessPET/CT scan improves detection of metastatic disease compared with CT scan alone in women with high-grade neuroendocrine cervical cancer: a NeCTuR study
Objective To determine the optimal imaging modality for women with high-grade neuroendocrine carcinoma of the cervix. Methods Women with high-grade neuroendocrine carcinoma of the cervix who had undergone a computed tomography (CT) scan and combined positron emission tomography with computed tomography (PET/CT) scan within 4 weeks of each other were identified from the NeCTuR Cervical Tumor Registry. One radiologist reviewed all CT scans, and another radiologist reviewed all PET/CT scans. The radiologists denoted the presence or absence of disease at multiple sites. Each radiologist was blinded to prior reports, patient outcomes, and the readings of the other radiologist. With findings on PET/CT used as the gold standard, sensitivity, specificity, and accuracy were calculated for CT scans. Results Fifty matched CT and PET/CT scans were performed in 41 patients. For detecting primary disease in the cervix, CT scan had a sensitivity of 85%, a specificity of 46%, and an accuracy of 74%. For detecting disease spread to the liver, CT scan had a sensitivity of 80%, a specificity of 89%, and an accuracy of 86%. For detecting disease spread to the lung, CT had a sensitivity of 89%, a specificity of 68%, and an accuracy of 77%. Of the 14 patients who had scans for primary disease work-up, 4 (29%) had a change in their treatment plan due to the PET/CT scan. Had treatment been prescribed on the basis of the CT scan alone, 2 patients would have been undertreated, and 2 would have been overtreated. Conclusion A CT scan is inferior to a PET/CT scan in assessment of metastatic disease in women with high-grade neuroendocrine carcinoma of the cervix. Almost one-third of patients with newly diagnosed high-grade neuroendocrine cervical cancer would have received incorrect therapy had treatment planning been based solely on a CT scan. We recommend a PET/CT scan for both initial work-up and surveillance in women with high-grade neuroendocrine carcinoma of the cervix.